
News|Articles|September 1, 2001
Trio of new studies help clarify role of abciximab
Abciximab reduces nonfatal outcomes as part of a new reperfusion regimen for acute myocardial infarction (MI) but appears not to benefit patients with acute coronary syndromes who don't undergo early revascularization.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves Simtriyo, the first triple reuptake inhibitor for ADHD
2
Long-acting HIV treatment still out of reach in low- and middle-income countries, says UCSF's Monica Gandhi | AIDS 2026
3
Long-acting cabotegravir PrEP users report no HIV infections, high satisfaction | AIDS 2026
4
Scientifically, lenacapavir PrEP takes a victory lap. But now worries about access | AIDS 2026
5


























